Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported July 30, as revenue rose about 17% to roughly $4.3 billion. Revenue of $4.29 billion topped the $3.82 billion consensus by +12.4% and was up from $3.68 billion a year earlier, while adjusted EPS of $14.29 beat the $10.16 estimate by +40.6% after rising from $12.89 a year ago. Net income was about $1.3 billion, down near 7% from about $1.4 billion a year earlier, while gross profit came in at about $4.2 billion with gross margin near 98% and operating margin around 30%. Operating cash flow was $813.0 million, the company repurchased about $1.2 billion of stock and paid about $96.8 million in dividends, and consensus for the next period calls for EPS of $13.07 on revenue of $4.34 billion.